Analysts' optimism about Bristol-Myers Squibb's earnings pot...

Analysts' optimism about Bristol-Myers Squibb's earnings potential has grown, but the improved EPS outlook isn't expected to boost the stock's long-term valuation. The company's revenue growth is predicted to slow significantly compared to its past growth rate and the anticipated growth of other industry players.